342 related articles for article (PubMed ID: 26935577)
1. Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma.
Duerinck J; Du Four S; Vandervorst F; D'Haene N; Le Mercier M; Michotte A; Van Binst AM; Everaert H; Salmon I; Bouttens F; Verschaeve V; Neyns B
J Neurooncol; 2016 May; 128(1):147-155. PubMed ID: 26935577
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma.
Duerinck J; Du Four S; Bouttens F; Andre C; Verschaeve V; Van Fraeyenhove F; Chaskis C; D'Haene N; Le Mercier M; Rogiers A; Michotte A; Salmon I; Neyns B
J Neurooncol; 2018 Jan; 136(1):115-125. PubMed ID: 28988341
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.
McNamara MG; Le LW; Horgan AM; Aspinall A; Burak KW; Dhani N; Chen E; Sinaei M; Lo G; Kim TK; Rogalla P; Bathe OF; Knox JJ
Cancer; 2015 May; 121(10):1620-7. PubMed ID: 25565269
[TBL] [Abstract][Full Text] [Related]
4. Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion.
Du Four S; Maenhout SK; Benteyn D; De Keersmaecker B; Duerinck J; Thielemans K; Neyns B; Aerts JL
Cancer Immunol Immunother; 2016 Jun; 65(6):727-40. PubMed ID: 27098427
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
[TBL] [Abstract][Full Text] [Related]
6. Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma.
Fruehauf J; Lutzky J; McDermott D; Brown CK; Meric JB; Rosbrook B; Shalinsky DR; Liau KF; Niethammer AG; Kim S; Rixe O
Clin Cancer Res; 2011 Dec; 17(23):7462-9. PubMed ID: 21976544
[TBL] [Abstract][Full Text] [Related]
7. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O
Cloughesy T; Finocchiaro G; Belda-Iniesta C; Recht L; Brandes AA; Pineda E; Mikkelsen T; Chinot OL; Balana C; Macdonald DR; Westphal M; Hopkins K; Weller M; Bais C; Sandmann T; Bruey JM; Koeppen H; Liu B; Verret W; Phan SC; Shames DS
J Clin Oncol; 2017 Jan; 35(3):343-351. PubMed ID: 27918718
[TBL] [Abstract][Full Text] [Related]
8. A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer.
Swiecicki PL; Zhao L; Belile E; Sacco AG; Chepeha DB; Dobrosotskaya I; Spector M; Shuman A; Malloy K; Moyer J; McKean E; McLean S; Wolf GT; Eisbruch A; Prince M; Bradford C; Carey T; Worden FP
Invest New Drugs; 2015 Dec; 33(6):1248-56. PubMed ID: 26453566
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma.
Weathers SP; Han X; Liu DD; Conrad CA; Gilbert MR; Loghin ME; O'Brien BJ; Penas-Prado M; Puduvalli VK; Tremont-Lukats I; Colen RR; Yung WKA; de Groot JF
J Neurooncol; 2016 Sep; 129(3):487-494. PubMed ID: 27406589
[TBL] [Abstract][Full Text] [Related]
10. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
[TBL] [Abstract][Full Text] [Related]
11. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
Reardon DA; Brandes AA; Omuro A; Mulholland P; Lim M; Wick A; Baehring J; Ahluwalia MS; Roth P; Bähr O; Phuphanich S; Sepulveda JM; De Souza P; Sahebjam S; Carleton M; Tatsuoka K; Taitt C; Zwirtes R; Sampson J; Weller M
JAMA Oncol; 2020 Jul; 6(7):1003-1010. PubMed ID: 32437507
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
Hainsworth JD; Shih KC; Shepard GC; Tillinghast GW; Brinker BT; Spigel DR
Clin Adv Hematol Oncol; 2012 Apr; 10(4):240-6. PubMed ID: 22706484
[TBL] [Abstract][Full Text] [Related]
13. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
[TBL] [Abstract][Full Text] [Related]
14. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Taal W; Oosterkamp HM; Walenkamp AM; Dubbink HJ; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; Boerman D; de Vos FY; Dinjens WN; Enting RH; Taphoorn MJ; van den Berkmortel FW; Jansen RL; Brandsma D; Bromberg JE; van Heuvel I; Vernhout RM; van der Holt B; van den Bent MJ
Lancet Oncol; 2014 Aug; 15(9):943-53. PubMed ID: 25035291
[TBL] [Abstract][Full Text] [Related]
15. Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy.
George E; Kijewski MF; Dubey S; Belanger AP; Reardon DA; Wen PY; Kesari S; Horky L; Park MA; Huang RY
AJR Am J Roentgenol; 2018 Dec; 211(6):1342-1347. PubMed ID: 30332289
[TBL] [Abstract][Full Text] [Related]
16. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF
Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma.
Lee EQ; Muzikansky A; Duda DG; Gaffey S; Dietrich J; Nayak L; Chukwueke UN; Beroukhim R; Doherty L; Laub CK; LaFrankie D; Fontana B; Stefanik J; Ruland S; Caruso V; Bruno J; Ligon K; Reardon DA; Wen PY
Cancer Med; 2019 Oct; 8(13):5988-5994. PubMed ID: 31444999
[TBL] [Abstract][Full Text] [Related]
18. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.
Tomita Y; Uemura H; Fujimoto H; Kanayama HO; Shinohara N; Nakazawa H; Imai K; Umeyama Y; Ozono S; Naito S; Akaza H;
Eur J Cancer; 2011 Nov; 47(17):2592-602. PubMed ID: 21889330
[TBL] [Abstract][Full Text] [Related]
19. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial.
Lombardi G; De Salvo GL; Brandes AA; Eoli M; Rudà R; Faedi M; Lolli I; Pace A; Daniele B; Pasqualetti F; Rizzato S; Bellu L; Pambuku A; Farina M; Magni G; Indraccolo S; Gardiman MP; Soffietti R; Zagonel V
Lancet Oncol; 2019 Jan; 20(1):110-119. PubMed ID: 30522967
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of recurrent glioblastoma with single-agent bevacizumab].
Sinkó D; Nemeskéri C
Orv Hetil; 2016 Mar; 157(13):500-3. PubMed ID: 26996897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]